Circulating levels of interleukin 10 and other cytokines in rheumatoid arthritis treated with cyclosporin A or combination therapy

Journal of Rheumatology

Volumn 25, Issue 10, 1998, Pages 1874-1879

  Ferraccioli, Gianfranco ^a   Falleti, Edmondo ^b   De Vita, Salvatore ^b   Di Poi, Emma ^b   Damato, Rosaria ^b   Casatta, Lucia ^b   Salaffi, Fausto ^b  

^a Section of Oncology and Molecular Pathology   (Italy)

^b NONE

Author keywords

Cyclosporin A; Early rheumatoid arthritis; Hydroxychloroquine; Interleukin 10

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOSPORIN A; CYTOKINE; HYDROXYCHLOROQUINE; INTERLEUKIN 10; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; RHEUMATOID FACTOR;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; FEMALE; HUMAN; INFLAMMATION; JOINT DESTRUCTION; MALE; ONSET AGE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOGLOBULINS; INTERLEUKIN-10; INTERLEUKINS; MALE; MIDDLE AGED;

EID: 0031750631     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Eng J Med 1990;322:1277-89.
2. Dolcetti R, Boiocchi M. Cellular and molecular basis of B cell clonal expansions. Clin Exp Rheumatol 1996;14:3-14.
3. Hirano T, Matsuda T, Turner MA, et al. Excessive production of IL6/B cell stimulating factor 2 in rheumatoid arthritis. Eur J Immunol 1988;18:1797-801.
4. Nijsten MWN, De Groot ER, Ten Duis HJ, Klasen HJ, Hack CE, Aarden LA. Serum levels of interleukin 6 and acute phase response. Lancet 1987;2:921-4.
5. Kotake S, Sato K, Kim JM. Interleukin 6 and soluble IL6 receptors found in synovial fluid are responsible for inducing joint disruption in patients with rheumatoid arthritis. J. Bone Miner Res 1994;9 Suppl 1:S140.
6. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin 6 receptor triggers osteoclast formation by IL-6. Proc. Natl Acad Sci USA 1993;90:11924-8.
7. Watson C, Whittaker S, Smith N, Vora AJ, Dumonde DC, Brown KA. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clin Exp Rheumatol 1996;105:112-9.
8. Maruo N, Morita J, Shirao M. IL-6 increases endothelial permeability in vitro. Endocrinology 1992;131:710-4.
9. Caldenhoven E, Coffer P, Yuan J. Stimulation of the human intercellular adhesion molecule 1 promoter by interleukin 6 and interferon Y involves binding of distinct factors to a palindromic response element. J Biol Chem 1994;269:21146-54.
10. Brandt SJ, Bodine DM, Dumbarc E. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990;86:592-9.
11. O'Garra A, Umland S, De France T, Christiansen JB. B cell factors are pleiotropic. Immunol Today 1988;9:45-54.
12. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opinion Immunol 1996;8:872-88.
13. Faulds D, Goa KL, Benfield P. Cyclosporin A: review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in immunoregulatory disorders. Drugs 1993;45:953-1040.
14. Crilly A, Kolta S, Dougados M, Sturrock RD, Amor B, Capell HA. Effect of cyclosporin A on interleukin 6 and soluble interleukin 2 receptor in patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:137-9.
15. Forre O, and the Norwegian Arthritis Study Group. Radiological evidence of disease modification in rheumatoid arthritis patients treated with cyclosporin. Arthritis Rheum 1994;37:1506-12.
16. Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996;39:1006-15.
17. Dijkmans BAC, Vandenborne BEEM, Landewe RBM, Miltenburg AMM, Verweij CL, Breedveld FC. Chloroquine combined with cyclosporin in rheumatoid arthritis: more than the addition of two drugs alone. J Rheumatol 1996;23 Suppl 44:61-3.
18. Tanner JE, Alfieri C. Interactions involving cyclosporin A, interleukin 6 and Epstein-Barr virus lead to the promotion of B cell lymphoproliferative disease. Leuk Lymphoma 1996;21:379-90.
19. Sperber K, Quraishi H, Kalb TH. Selective regulation of cytokine secretion by hydroxychloroquine inhibition of IL-1 and IL-6 in human monocytes and T cells. J Rheumatol 1993;20:803-8.
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
22. International Consensus Report: the use of cyclosporin A in rheumatoid arthritis. Br J Rheumatol 1993;32 Suppl 1:1-3.
23. Van Gestel AM, Prevoo MLL, Van't Hof MA, Van Rijswijk HM, Van De Putte LBA, Van Riel PLCM. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
24. Beaume A, Brizard A, Dreyfus B, Preud'homme JL. High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B cell chronic lymphocytic leukemia. Blood 1994;84:1216-9.
25. Edwards JC, Cambridge J. Is rheumatoid arthritis a failure of B cell death in synovium? Ann Rheum Dis 1995;54:696-700.
26. Smiley JD, Sachs C, Ziff M. In vitro synthesis of immunoglobulin by rheumatoid synovial membrane. J Clin Invest 1968;47:624-32.
27. Guillemin F, Bene MC, Aussedat R, et al. Pre-B lymphocytes with intracytoplasmic μ chain in the peripheral blood of rheumatoid arthritis patients. Clin Immunol lmmunopathol 1990;57:308-16.
28. McGee B, Small RE, Singh R, et al. B lymphocytic clonal expansion in rheumatoid arthritis. J Rheumatol 1996;23:36-43.
29. Barrera P, Boerbooms AMT, Van De Putte LBA, Van Der Meer JWM. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 1996;25:234-53.
30. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996;14:397-440.
31. Schindler R, Manculla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of IL-6, IL-1 and TNF in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990;75:40-7.
32. Van De Loo FAJ, Joosten LAB, Van Lent P, Arntz OJ, van den Berg WB. Role of interleukin 1, tumor necrosis factor α and interleukin 6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-72.
33. Van De Loo FAJ, Kuiper S, Van Enckevort FHJ, Arntz OJ, van den Berg WB. IL-6 ameliorates cartilage destruction during experimental arthritis: a study in IL-6 deficient mice. Am J Pathol 1997;151:177-91.
34. Cush JJ, Splawski JB, Thomas R, et al. Elevated interleukin levels in patients with rheumatoid arthritis. Arthritis Rheum 1995;38:96-104.
35. Katsikis P, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 (IL-10) in rheumatoid arthritis. J Exp Med 1994;179:1517-27.
36. Kasama T, Strieter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL. Interleukin 10 expression and chemokine regulation during the evolution of murine type II collagen induced arthritis. J Clin Invest 1995;95:2868-76.
37. Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-3.
38. Clayberger C, Luna-Fineman S, Lee JE, et al. Interleukin 3 is a growth factor for human follicular B cell lymphoma. J Exp Med 1992;175:371-6.
39. Caux CH, Vanbervliet B, Massacrier C, Durand L, Banchereau J. Interleukin 3 cooperates with tumor necrosis factor for the development of human dendritic/Langerhans cells from cord blood CD 34+ hematopoietic progenitor cells. Blood 1996;87:2376-80.
40. Dechanet J, Merville P, Durand I, Banchereau J, Miossec P. The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium. J Clin Invest 1995;95:456-63.
41. Trinchieri G. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cell type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
42. Germann T, Szeliga J, Hess H, et al. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci USA 1995;92:4823-7.
43. Jelinek DF, Braaten JK. Role of IL-12 in human B lymphocyte proliferation and differentiation. J Immunol 1995;154:1606-13.
44. Bucht A, Larsson P, Weisbrot L, et al. Expression of interferon γ, IL-10, IL-12 and transforming growth factor β m-RNA in synovial cells from patients in the early and late phases of rheumatoid arthritis. Clin Exp Rheumatol 1996;103:357-67.